Nabi Biopharmaceuticals (NASDAQ: NABI) today announced the initiation of a Phase I/II clinical trial for two of the antigens in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE